MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Manifestations of aging and Parkinson’s Disease in low-frequency fluctuations of postural sway velocity

    M. Latka, K. Kozlowska, A. Latka, M. Glaubic-Latka, S. Budrewicz, M. Koszewicz, T. Sebzda, BJ. West (Wroclaw, Poland)

    Objective: To distinguish the effects of aging and Parkinson's disease on balance control. Background: Many balance control measures are derived from spontaneous fluctuations of the center…
  • 2023 International Congress

    Preliminary evidence for evolution of myoinositol and N-acteylaspartate as biomarkers of disease severity in early-stage multiple system atrophy

    P. Trujillo, J. Iregui, K. Hett, A. Wynn, M. Donahue, C. Wong, D. Stamler, D. Claassen (Nashville, USA)

    Objective: To quantify the longitudinal evolution of metabolic indicators of gliosis and neuronal integrity in patients with multiple system atrophy (MSA) over one year. Background:…
  • 2023 International Congress

    Screening risk of falls in Parkinson’s disease population living in underserved areas

    T. Capato, J. Miranda, F. Santos, R. Cury, E. Barbosa (São Paulo, Brazil)

    Objective: To verify the feasibility of the Balance-App to assess the risk of falls in the PD population living in underserved areas. Background: The screening…
  • 2023 International Congress

    Early-onset levodopa-responsive Parkinsonism associated with dysarthria, pyramidalism, and dystonia: a rare condition that can benefit from a combined treatment approach.

    L. Gallo, M. Avenali, P. Mitrotti, C. Tassorelli, R. Zangaglia, F. Valentino, S. Gana, EM. Valente, C. Pacchetti, G. Cosentino (Pavia, Italy)

    Objective: To describe a rare case of early-onset parkinsonism (EOP) successfully treated with a combined therapeutic approach. Background: EOP is a rare condition manifesting with…
  • 2023 International Congress

    Motor phenotype and disease burden among Parkinson’s disease patients of Addis Ababa, Ethiopia.

    B. Getahun, H. Demissie, H. Nuri, S. Gugssa (Dire Dawa, Ethiopia)

    Objective: This study aims to characterize the motor phenotype of Parkinson’s disease (PD), compare disease severity and to determine quality of life among the different…
  • 2023 International Congress

    Ultra long-term outcome of deep brain stimulation (DBS) compared to botulinum toxin (BoNT) treatment in cervical dystonia (CD)

    IM. Wedding, V. Siewers, IM. Skogseid (Oslo, Norway)

    Objective: To compare residual symptoms and disease-specific quality of life (DS-QoL) in CD patients treated with DBS, or BoNT injections alone, for minimum 3 years.…
  • 2023 International Congress

    Use of insect model to study Parkinson’s disease pathophysiology by inducing GSH-depletion and behavioral deficits among larvae: Evidences of ameliorative properties of phytoconstituents

    G. Chandran, R. D'Silva, M. Muralidhara (MYSURU, India)

    Objective: The purpose of the study is to establish an all-around model for Parkinson's disease using Drosophila melanogaster, the fruit-fly in order to understand  behavioral…
  • 2023 International Congress

    Crushing valbenazine capsule contents for potential addition to soft foods or administration via G tube

    M. Hebert, A. Mar, R. Moore, A. Bristow, S. Siegert (San Diego, USA)

    Objective: To evaluate the suitability of mixing crushed contents from valbenazine capsules with soft foods/liquids or adding them to water for delivery through a gastrostomy…
  • 2023 International Congress

    Evaluating the efficacy of dextromethorphan/quinidine (DM/Q) in treating irritability in Huntington’s disease

    E. Furr Stimming, S. Abdollah Zadegan, J. Patino, N. Rocha (Houston, USA)

    Objective: To prove the efficacy and safety of dextromethorphan/quinidine 20mg/10mg (Nuedexta®) in patients with irritability due to HD. Background: Irritability is one of HD's most…
  • 2023 International Congress

    Understanding caffeine consumption in Huntington’s Disease

    J. Adrissi, S. Brooker, A. Mcbride, D. Larson, E. Gausche, D. Bega (Los Angeles, USA)

    Objective: The purpose of this study is to better understand the amount of caffeine consumption in people with HD and the subjective motivations and consequences…
  • « Previous Page
  • 1
  • …
  • 591
  • 592
  • 593
  • 594
  • 595
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley